NICE recommends dropping two drugs from Cancer Drugs Fund
BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4562 (Published 18 August 2016) Cite this as: BMJ 2016;354:i4562
- Nigel Hawkes
- London
Two drugs currently provided under the Cancer Drugs Fund (CDF) should cease to be available because they are not cost effective, the National Institute for Health and Care Excellence (NICE) has concluded.
Everolimus for breast cancer (Afinitor, Novartis) and ibrutinib for mantle cell lymphoma (Imbruvica, Janssen) do not meet the grade, says NICE in draft guidance now open for consultation.1 2
Under its new operating model the CDF acts as a gateway fund for new cancer drugs, with NICE calling the shots. In the former model the fund made its own decisions …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.